Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Chung, Sang Wan | - |
dc.contributor.author | Pyo, Jung Yoon | - |
dc.contributor.author | Chang, Sung Hae | - |
dc.contributor.author | Kim, Min Uk | - |
dc.contributor.author | Park, Chan Ho | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Lee, Jeong Seok | - |
dc.contributor.author | Ha, You-Jung | - |
dc.contributor.author | Kang, Eun Ha | - |
dc.contributor.author | Lee, Yeon-Ah | - |
dc.contributor.author | Park, Yong-Beom | - |
dc.contributor.author | Lee, Eun Young | - |
dc.contributor.author | Choe, Jung-Yoon | - |
dc.date.accessioned | 2023-03-09T02:42:10Z | - |
dc.date.available | 2023-03-09T02:42:10Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.issn | 1462-0332 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22089 | - |
dc.description.abstract | Objective To examine the association between MTX, LEF and tacrolimus use and the progression of RA-associated interstitial lung disease (ILD). Methods The Korean RA-ILD cohort prospectively enrolled patients with RA-associated ILD at multiple centres from 2015 to 2018 and followed up with them for 3 years. ILD progression was defined by any of the followings: a decrease of >= 10% in forced vital capacity, a decrease of >= 15% in the diffusing capacity of the lung for carbon monoxide, or death from respiratory failure. Results Of 143 patients, 64 patients experienced ILD progression during a median follow-up period of 33 months. The use of MTX [adjusted hazard ratio (aHR), 1.06; 95% CI, 0.59, 1.89], LEF (aHR, 1.75; 95% CI, 0.88, 3.46) and tacrolimus (aHR, 0.94; 95% CI, 0.52, 1.72) did not increase the risk of ILD progression. However, the association between LEF use and the risk of ILD progression was significant in subgroups with poor lung function (aHR, 8.42; 95% CI, 2.61, 27.15). Older age, male sex, a shorter RA duration, higher RA disease activity and extensive disease at baseline were independently associated with ILD progression. Conclusion None of the three treatments increased the risk of RA-associated ILD progression, except for LEF, which increased the risk of ILD progression in patients with severe ILD. The appropriate use of conventional synthetic disease-modifying antirheumatic drugs considering RA disease activity and ILD severity would be important for the management of RA-associated ILD. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Oxford University Press | - |
dc.title | Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1093/rheumatology/keac651 | - |
dc.identifier.scopusid | 2-s2.0-85164240714 | - |
dc.identifier.wosid | 000897732800001 | - |
dc.identifier.bibliographicCitation | Rheumatology, v.62, no.7, pp 2377 - 2385 | - |
dc.citation.title | Rheumatology | - |
dc.citation.volume | 62 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 2377 | - |
dc.citation.endPage | 2385 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | IDIOPATHIC PULMONARY-FIBROSIS | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ACUTE EXACERBATION | - |
dc.subject.keywordPlus | AMERICAN-COLLEGE | - |
dc.subject.keywordPlus | INJURY | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | PNEUMONITIS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordAuthor | RA | - |
dc.subject.keywordAuthor | interstitial lung disease | - |
dc.subject.keywordAuthor | MTX | - |
dc.subject.keywordAuthor | LEF | - |
dc.subject.keywordAuthor | tacrolimus | - |
dc.subject.keywordAuthor | progression-free survival | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.